Status:
RECRUITING
Disentangling the Variability of Exercise-induced Hypoalgesia: the Role of Circulatory Compounds
Lead Sponsor:
Université Catholique de Louvain
Conditions:
Healthy
Eligibility:
All Genders
18-30 years
Phase:
NA
Brief Summary
Physical exercise is increasingly recognized as an effective treatment for chronic pain. Studies in humans and animals have shown that a single session of exercise induces a reduction of sensitivity t...
Eligibility Criteria
Inclusion
- Males, or females using hormonal contraception since ≥ 3 months.
- Aged between 18 and 30 years.
- Ability to provide written informed consent.
- Fluency in French or English.
- BMI between 17 and 30 kg/cm2.
Exclusion
- Regular tobacco use (\> 1/month)
- Not willing or able to abstain from alcohol, recreational drugs, coffee, or tea from 24 hours prior to each experimental session.
- Not willing or able to restrain from physical activity \> 24h prior to each experimental session, and to be in a fasted state on the day of each experimental session.
- Any evidence for neurological, cardiovascular, respiratory, inflammatory, endocrine, psychiatric, oncological, rheumatological conditions on direct questioning.
- Presence of any medical devices (e.g., cardiac pacemaker) implants or prothesis unless it is beyond discussion that these will not put the subject's safety during the study at risk and will not interfere with the results of the study.
- Any chronic pain condition or recent history thereof (i.e., within the preceding 2 years).
- Wounds or skin alteration on testing sites.
- Surgery \< 12 months.
- Any drug intake in the past 2 weeks including antibiotics, herbal medicines and other remedies except the following drugs that will be allowed up to 48 hours prior to the experiments: oral paracetamol or ibuprofen for a self-limiting condition (e.g. toothache, bruise). Oral antihistaminics and nasal aerosol and topical treatments for seasonal allergy up to 1 week before the experimental session.
- Any physical activity contraindication.
- Pregnancy.
Key Trial Info
Start Date :
April 14 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06967714
Start Date
April 14 2025
End Date
April 1 2026
Last Update
May 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLouvain, Institute of neuroscience
Brussels, Belgium, Belgium, 1200